Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.
Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.
Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.
The company's product pipeline includes two promising therapies:
- SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
- SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.
Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.
Silence Therapeutics (Nasdaq: SLN) announced its participation in the Jefferies Global Healthcare Conference on June 6th at 2:30 p.m. ET. The company, known for its innovative biotechnology solutions aimed at silencing diseases through precision-engineered medicines, will provide a presentation accessible via live webcast on the company's investor section. An archived replay will also be available after the event.
Silence Therapeutics (NASDAQ: SLN) disclosed its Q1 2024 financials and recent advancements. The firm reported a cash position of £152.8 million ($192.8 million), up from £62.9 million ($77.8 million) a year prior. Collaboration revenue rose by £1.0 million to £12.4 million, largely due to a £9.2 million milestone payment from AstraZeneca. R&D expenses decreased by £3.4 million to £9.2 million, and G&A expenses dropped by £1.3 million to £5.2 million. This resulted in a net loss of £1.9 million, a significant improvement from the £10.2 million loss last year.
Key pipeline updates included positive 36-week data from the phase 2 ALPACAR-360 study of zerlasiran for cardiovascular disease, with primary endpoints met and no new safety concerns. Additionally, promising phase 1 data for divesiran in polycythemia vera (PV) patients were reported. Collaboratively, Silence achieved a $10 million milestone from AstraZeneca after initiating a phase 1 trial.
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The Company focuses on precision engineered medicines to silence diseases, aiming to transform people's lives. The event will take place on May 20th, 2:30 p.m. ET, with a live webcast accessible on the Silence website and an archived replay available post-conference.
Silence Therapeutics plc announced the retirement of Alistair Gray, an independent member of the Board of Directors since 2015, effective May 1, 2024. Alistair Gray made significant contributions during his tenure, marking a period of growth and transformation for the company under the leadership of Iain Ross and Craig Tooman. The Company transitioned into a global player focusing on RNA interference, developed a pipeline of innovative product candidates, and secured big pharma partnerships.
FAQ
What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?
What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?
What is Silence Therapeutics Plc?
What is RNA interference (RNAi)?
What is SLN360 therapy?
What is SLN124 therapy?
How does Silence Therapeutics target specific cells?
What diseases are Silence Therapeutics' therapies targeting?
How does SLN360 reduce cardiovascular risks?
What is the role of hepcidin in SLN124 therapy?
Where can I find more information about Silence Therapeutics' projects?